A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effects.

dc.contributor.author	Lin HX.
dc.contributor.author	Gontier Christopher Stuart.
dc.contributor.author	Saron MF.
dc.contributor.author	Perrin P.
dc.date.accessioned	2013-06-23T08:33:07Z
dc.date.available	2013-06-23T08:33:07Z
dc.date.issued	1993
dc.identifier.citation	Lin HX, Gontier C, Saron MF, Perrin P.,A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effects.,Arch Virol. 1993;131(3-4):307-19.	en
dc.identifier.uri	http://www.ncbi.nlm.nih.gov/pubmed/7688505
dc.identifier.uri	http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/38394
dc.description.abstract	The activity of an immunostimulatory complex (PICKCa) which is widely used against several human diseases in China was tested in experimental rabies prophylaxis. PICKCa protected mice against peripheral infection with both fixed and wild rabies strains. It also enhanced the protective activity of an experimental rabies vaccine injected either before or after rabies infection. PICKCa enhanced both non-specific immune responses and specific immunity including antibody production and cell mediated immunity as assessed by interleukin-2 production.	en
dc.language.iso	en	en
dc.publisher	University of Nairobi,	en
dc.title	A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effects.	en
dc.type	Article	en
local.publisher	Department of Human Pathology,	en